Financial Advocates Investment Management’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-573
Closed -$39.3K 699
2023
Q2
$39.3K Buy
+573
New +$41.9K ﹤0.01% 687
2023
Q1
Sell
-735
Closed -$83.9K 751
2022
Q4
$102K Sell
735
-1,519
-67% -$214K 0.01% 719
2022
Q3
$3.54M Buy
2,254
+1,732
+332% +$196K 0.29% 89
2022
Q2
$43K Sell
522
-70
-12% -$5.43K ﹤0.01% 669
2022
Q1
$57K Sell
592
-100
-14% -$13.2K ﹤0.01% 715
2021
Q4
$138K Sell
692
-2,800
-80% -$661K 0.01% 745
2021
Q3
$1.31M Buy
3,492
+3,089
+767% +$883K 0.09% 257
2021
Q2
$681K Sell
403
-2,069
-84% -$820K 0.05% 409
2021
Q1
$1.17M Buy
2,472
+2,232
+930% +$1.1M 0.08% 279
2020
Q4
$310K Buy
+240
New +$152K 0.02% 554

Other funds holding BLUE

Financial Advocates Investment Management's BLUE Position: Q3 2023 in Review

Financial Advocates Investment Management sold out of bluebird bio (BLUE) in Q3 2023, closing a stake of 573 shares — an estimated $39.3K sold.

Financial Advocates Investment Management first reported a position in BLUE in Q4 2020 and held it in 10 quarters. The position peaked at $3.54M in Q3 2022. 168 funds tracked by Wall St. Rank hold BLUE as of Q3 2023.

  • Financial Advocates Investment Management reported no remaining bluebird bio position as of Q3 2023 after selling out during the quarter.
  • Financial Advocates Investment Management sold 573 bluebird bio shares in Q3 2023, an estimated $39.3K.
  • Financial Advocates Investment Management first reported a position in bluebird bio in Q4 2020 and held it in 10 quarters.
  • Financial Advocates Investment Management's bluebird bio position peaked at $3.54M in Q3 2022.
  • 168 funds tracked by Wall St. Rank held bluebird bio as of Q3 2023.

Based on Financial Advocates Investment Management's 13F filing for Q3 2023, filed 27 Oct 2023.